Search

Displaying results 2211 - 2220 of 7687 in total
  1. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099]. … While standard ERTs can treat systemic symptoms, they are unable to cross the blood-brain barrier (BBB) to address the progressive cognitive decline and neurological impairment seen in the majority of

    Synonyms: -bis(disulfide) with immunoglobulin Fcab anti-(human type 1 transferrin receptor) (synthetic hu
  2. Target

    Folate receptor

    go.drugbank.com/bio_entities/BE0010260
    TransporterTargetHumans

    Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells (PubMed:19074442, PubMed:23851396, PubMed:23934049, PubMed:2527252, PubMed:8033114, PubMed...

    Synonyms: FR-alpha, FR-beta
  3. Drug

    Indigotindisulfonic acid

    go.drugbank.com/drugs/DB11577
    ApprovedInvestigational

    This compound is an acid-base indicator and is used in the production of food colorants and pH tests. … [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to aid in visualizing ureter integrity in cystoscopic assessments.[L42600]

  4. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    The cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.

  5. Drug

    Valoctocogene roxaparvovec

    go.drugbank.com/drugs/DB15561
    ApprovedInvestigationalWithdrawn

    [L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ).

  6. Drug

    Pramlintide

    go.drugbank.com/drugs/DB01278
    ApprovedInvestigational

    Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a...

  7. Drug

    Donislecel

    go.drugbank.com/drugs/DB17961
    Approved

    [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196]

  8. Drug

    Clopenthixol

    go.drugbank.com/drugs/DB13841
    Investigational

    It is an antagonist at D1 and D2 dopamine receptors.

  9. Drug

    Antihemophilic factor, human recombinant

    go.drugbank.com/drugs/DB00025
    ApprovedInvestigational

    Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

    Products: KOGENATE-FS for Injection 500 iu/vial, KOGENATE-FS for Injection 250 iu/vial
  10. Drug

    Megestrol acetate

    go.drugbank.com/drugs/DB00351
    ApprovedInvestigationalVet approved

    As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.